Kisspeptin: KISS1R Signaling in Research

Kisspeptins are a set of RF-amide peptides cut from one precursor, the product of the human KISS1 gene, and they are the natural ligands of the G protein-coupled receptor KISS1R, formerly the orphan receptor GPR54. The reagent usually sold as kisspeptin is kisspeptin-10, the C-terminal decapeptide Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (C63H83N17O14, 1302.4 g/mol, CAS 374675-21-5). Receptor activation runs through Gq/11 and phospholipase C, and the KISS1/KISS1R pair is the system that 2003 genetics linked to the gonadotropin-releasing hormone axis.

The compound has an unusual history: it was found as a metastasis-suppressor gene product, matched to an orphan receptor by three groups in one year, and only then connected to reproductive neuroendocrinology. This profile covers the identity data, the processing of the precursor, the signaling pathway, the research systems in use, and how the peptide behaves in a vial.

Kisspeptin-10 at a glance

The C-terminal amide is not optional decoration. Every active kisspeptin ends in Arg-Phe-NH2, the motif that defines the RF-amide peptide family, and it is the part of the molecule the receptor reads. A synthesis that fails to amidate the C-terminus gives a free acid that is a different compound.

One precursor, four named peptides

KISS1 encodes a 138-residue precursor with a signal sequence. Proteolysis of that precursor gives a 54-residue peptide and three shorter ones, all sharing the same C-terminus.

Because they end at the same residue, all four carry the Phe-amide and all four are agonists at KISS1R. Kisspeptin-10 is the common laboratory reagent because it is the shortest fragment that retains full receptor activity and the easiest to make by solid-phase synthesis; kisspeptin-54 is closer to the circulating form. The naming inconsistency in older papers — metastin, KiSS-1 peptide, kisspeptin-54 — all refers to the same 54-residue species.

From a metastasis-suppressor gene to an orphan receptor

In 1996 Lee, Welch and colleagues, working at the Pennsylvania State University campus in Hershey, transferred human chromosome 6 into melanoma cell lines and looked for the messenger RNA that appeared when the cells lost the ability to metastasize. They named the resulting complementary DNA KiSS-1 and reported it in the Journal of the National Cancer Institute as a melanoma metastasis-suppressor gene, expressed most strongly in placenta. Their paper predicted a 164-residue protein product; the current human reference entry, UniProt Q15726, is 138 residues.

Five years later three groups independently matched the gene product to an orphan receptor.

• Ohtaki and colleagues at Takeda (Nature, 2001) isolated a C-terminally amidated 54-residue peptide from human placenta as the ligand of the orphan receptor hOT7T175, named it metastin, and reported that it inhibited chemotaxis and invasion of receptor-transfected CHO cells in vitro.
• Kotani and colleagues in Brussels (Journal of Biological Chemistry, 2001) isolated 54-, 14- and 13-residue peptides with a common RF-amide C-terminus from human placenta, named them kisspeptins, and showed low-nanomolar binding to rat and human GPR54 expressed in CHO-K1 cells, with PIP2 hydrolysis, calcium mobilization, arachidonic acid release, ERK1/2 and p38 MAP kinase phosphorylation, and stress fiber formation.
• Muir and colleagues at GlaxoSmithKline (Journal of Biological Chemistry, 2001) cloned the human receptor from a brain complementary DNA library, called it AXOR12, noted 81 percent homology to rat GPR54, and mapped its messenger RNA to brain, pituitary gland and placenta.

The receptor therefore carries four names in the literature — GPR54, AXOR12, OT7T175 and KISS1R — and a database search for any one of them returns the same 398-residue class A receptor.

The 2003 genetics that redirected the field

Two papers published in 2003 changed what the system was studied for. De Roux and colleagues mapped a consanguineous family with isolated hypogonadotropic hypogonadism to chromosome 19p13 and found that affected siblings carried a homozygous 155-nucleotide deletion in GPR54 spanning the intron 4-exon 5 junction. Seminara and colleagues, in the New England Journal of Medicine, described an L148S mutation in one pedigree and compound R331X and X399R mutations in an unrelated patient, showed reduced inositol phosphate accumulation when the mutant receptors were transfected into COS-7 cells, and phenotyped a Gpr54-deficient mouse line that failed to enter puberty while remaining responsive to exogenous gonadotropin-releasing hormone.

Together those two papers established that a loss-of-function receptor blocks the gonadotropin axis upstream of the hormone itself — the finding that made kisspeptin a neuroendocrine research tool rather than an oncology one.

Receptor pharmacology and signaling

KISS1R is a class A (rhodopsin-like) GPCR of 398 residues. The canonical pathway, as summarized in the UniProt annotation and in a 2022 review in Frontiers in Endocrinology, runs as follows:

1. Kisspeptin binds KISS1R and the receptor couples to Gq/11.
2. Phospholipase C hydrolyzes phosphatidylinositol 4,5-bisphosphate to inositol trisphosphate and diacylglycerol.
3. Inositol trisphosphate raises intracellular calcium.
4. In gonadotropin-releasing hormone neurons, that rise inhibits inward-rectifier potassium channels and activates TRPC-like cation channels, depolarizing the cell.
5. In parallel, β-arrestin-dependent signaling produces ERK1/2 phosphorylation.

A 2024 cryo-electron microscopy study of KISS1R in complex with the synthetic agonist TAK-448 reported structures of both Gq- and Gi-coupled complexes, showing that the receptor engages Gi/o in addition to the long-established Gq/11 pathway.

The 2022 review also describes the anatomy the pathway sits in: kisspeptin neurons in the arcuate nucleus co-express neurokinin B and dynorphin and are known as KNDy neurons, and they are the cells through which estrogen feedback reaches gonadotropin-releasing hormone release.

How kisspeptin signaling controls reproductive hormone release

Kisspeptin is a naturally occurring neuropeptide hormone, and hypothalamic kisspeptin plays its best-studied role in upstream control of the reproductive hormone cascade known as the hypothalamic-pituitary-gonadal (HPG) axis. UniProt describes the hypothalamic KISS1/KISS1R system as playing a central role in regulating that axis by modulating the secretion of gonadotropin-releasing hormone (GnRH) from GnRH neurons. The 2022 review puts it more simply: kisspeptin sits at the top of the HPG axis.

The cascade has three steps.

1. Hypothalamus. Kisspeptin neurons release the peptide, kisspeptin binds the kisspeptin receptor on GnRH neurons, and kisspeptin stimulates GnRH secretion.
2. Pituitary. GnRH acts on the pituitary gland. The UniProt entry for the GnRH precursor records that it stimulates the secretion of both gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
3. Gonads. LH and FSH act on the testes and ovaries. The UniProt entry for the LH beta subunit records that the hormone stimulates the testes and ovaries to synthesize steroids, the class that includes the androgen testosterone.

Kisspeptin therefore regulates LH and FSH, and any reproductive hormone made in the gonads such as testosterone, only indirectly, through GnRH. The review notes that a GnRH antagonist blocks the effect of kisspeptin on hormone release, which is the evidence for that ordering. It also explains the 2003 genetics: a receptor that cannot signal leaves the pituitary and gonads intact but removes the input they wait for, so normal reproductive function fails at the first step.

The same review describes how the sex steroids feed back on kisspeptin signaling. In rodents, estradiol inhibits kisspeptin neurons in the arcuate nucleus, which carry negative feedback, and stimulates a second population in the anteroventral periventricular region, which is tied to positive feedback. In humans, kisspeptin neurons lie mainly in the infundibular nucleus of the hypothalamus.

Research systems

Kisspeptin-10 appears in three kinds of experiment, and the assay format follows the pathway.

• Recombinant receptor assays. CHO-K1 or HEK293 cells expressing KISS1R, with calcium flux, accumulated inositol monophosphate or β-arrestin recruitment as the readout. This is the format the 2001 deorphanization papers used and the one a concentration-response curve is normally built in.
• Neuroendocrine preparations. Hypothalamic slices and immortalized gonadotropin-releasing hormone neuron lines, where the electrophysiological consequence described above — potassium channel inhibition and cation channel activation — is measured directly, and Gpr54-null mice as the genetic control.
• Cell migration and invasion assays. The original oncology context: receptor-transfected CHO or melanoma lines in chemotaxis and invasion chambers, where the 2001 papers reported inhibition of migration and of proliferation.

Because kisspeptin-10, -13, -14 and -54 are all agonists at the same receptor, a study that compares them is comparing stability and distribution rather than intrinsic receptor activity, and the fragment used should always be named explicitly in a method.

Kisspeptin-10 is also a convenient reference RF-amide when a laboratory is characterizing other hypothalamic neuropeptides side by side, such as oxytocin, which is a nonapeptide acting at its own class A receptor rather than at KISS1R.

Regulatory status

No kisspeptin has an approved application with the FDA, and no approved product in the United States contains one. Investigational human trials of kisspeptin peptides are registered on ClinicalTrials.gov, including academic studies of the gonadotropin axis; registration records a study, not an approval.

Anhydrolabs supplies kisspeptin as a research reagent for in-vitro laboratory work, not for human or veterinary diagnosis, treatment, or consumption. The terms are on the research use page.

Handling kisspeptin-10 in the laboratory

The reagent is supplied as a lyophilized powder in vacuum-sealed vials, and in 10-vial kits. Three features of the sequence drive its handling: the C-terminal amide, the hydrophobic Trp-Leu-Phe content, and the single arginine.

• Solubility. Kisspeptin-10 is amphipathic, with a polar N-terminal half and a hydrophobic C-terminal half. Water usually works for a concentrated stock; a small volume of dilute acetic acid or a low percentage of an organic co-solvent helps if the powder is slow to wet. The general method is in how to reconstitute peptides.
• Adsorption. Short amphipathic peptides bind glass and untreated polypropylene at low concentration, which is a common source of an apparently weak curve. Low-binding tubes, and a carrier protein in working dilutions below the micromolar range, are the usual precautions.
• Storage. Sealed vials are held cold, dry and dark, with −20 °C the usual long-term condition. Allow the vial to warm to room temperature before opening so moisture does not condense on the powder; see how to store peptides.
• Aliquots. Stocks are best divided into single-use volumes and frozen. The amide terminus and the asparagine residues are the slow liabilities in solution: asparagine deamidation is favored at alkaline pH, so stocks are normally kept near neutral or mildly acidic.
• Concentration checks. With one Trp and one Tyr, kisspeptin-10 has a well-defined molar absorptivity near 280 nm, so a spectrophotometric reading can verify a stock against the mass and peptide content stated on the certificate of analysis.
• Identity. A mass measurement distinguishes the amide (1302.4 g/mol) from the free acid, which is one dalton heavier, and from truncated sequences. Related peptides in the same family — kisspeptin-13 and -14 — differ by whole residues and are easy to resolve by mass; the same is true against structurally unrelated cyclic peptides such as Melanotan II.